AUTL Autolus Therapeutics ADS

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

LONDON, April 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will host an R&D investor event on Wednesday, April 23, 2025 at 8:30am EDT / 13:30pm BST.

Autolus will present an update on clinical pipeline programs, including plans to expand the obe-cel opportunity. The Company expects to report initial data in six patients from the ongoing CARLYSLE Phase 1 trial in systemic lupus erythematosus (SLE), announce development plans for expansion in autoimmune diseases, and provide a brief update of the ongoing commercial launch of AUCATZYL®.

A webcast of the presentation will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at . A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

The live event will be held in New York City. To inquire about in-person attendance please email:

About Autolus Therapeutics plc

Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit

Contact:

Amanda Cray 

 

 

Olivia Manser 

8 

 



EN
01/04/2025

Underlying

AUTLAutolus Therapeutics ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Autolus Therapeutics ADS

Jacob Mekhael
  • Jacob Mekhael
AUTL Autolus Therape...

Autolus Aucatzyl secures UK MHRA approval in r/r adult ALL, all eyes o...

Last Friday evening, Autolus announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation for Aucatzyl (CD19 CAR-T) in adult relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), in line with the expected timeline. Looking ahead, Autolus will report its 1Q25 results on 8 May, where the first quarter US sales of Aucatzyl will be reported and will give us a quantitative view on the launch momentum – note that ...

AUTL AUTOLUS THERAPEUTICS ADS
15h / 34m 15h / 34m 1 EN
Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi
TWEKA TKH GROUP N.V. CERT
MRUS MERUS B V
ARGX ARGEN-X SE
AUTL AUTOLUS THERAPEUTICS ADS
AKZA AKZO NOBEL N.V.
DEME DEME GROUP NV
15h / 44m 15h / 44m 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene auto...

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1) UK Medicines and Healthcare products Regulatory Agency (MHRA) authorisation based on FELIX clinical trial of obecabtagene autoleucel in adult patients with r/r B-ALL1AUCATZYL® licensed from MHRA under ‘conditional marketing authorisation’, meaning that the MHRA will review new efficacy and safety information at least once every year1 Investors, US and UK National, Medical and ...

April 25, 2025 1 EN
Guy Sips ... (+10)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Lewi
KPN ROYAL KPN NV
ZLDPF Zealand Pharma ... ... (+13)

Morning Notes : FLOW NA, FUR NA, GLPG NA, KIN BB, KPN NA, XFAB FP, AZE...

: FLOW NA, FUR NA, GLPG NA, KIN BB, KPN NA, XFAB FP, AZE BB, IMCD NA, ONWD BB, AUTL US, EXO NA, ZEAL DC, PHVS US

KPN ROYAL KPN NV
ZLDPF ZEALAND PHARMA A/S
KIN KINEPOLIS GROUP NV
INX IMCD N.V.
GLPG GALAPAGOS NV
EXO EXOR N.V.
XFAB X-FAB SILICON FOUNDRIES SE
AUTL AUTOLUS THERAPEUTICS ADS
PHVS PHARVARIS NV
FUR FUGRO NV
AZE AZELIS GROUP NV
ONWD ONWARD MEDICAL NV
FLOW FLOW TRADERS LTD
04/24/25 April 24, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
AUTL Autolus Therape...

Autolus R&D day outlines SLE data and path to market, MS up next

Yesterday, Autolus hosted an R&D day where it shared initial data from the phase 1 trial of obe-cel (CD19 CAR-T) in r/r SLE which showed that 3/6 patients achieved complete renal response (CRR). The company has aligned with the FDA on the route to market, and plans to initiate a pivotal phase 2 trial by YE25. In addition, Autolus announced its plan to evaluate obe-cel in progressive MS with a dose escalation trial due to begin by YE25. We reiterate our $ 10 TP and Buy rating.

AUTL AUTOLUS THERAPEUTICS ADS
04/24/25 April 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch